Entasis Therapeutics Announces the Appointment of Elizabeth Keiley as General Counsel
April 16, 2019 08:00 ET
|
Entasis Therapeutics Holdings Inc.
WALTHAM, Mass., April 16, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel...
Entasis Therapeutics Announces Multiple Data Presentations at ECCMID 2019
April 10, 2019 08:00 ET
|
Entasis Therapeutics Holdings Inc.
WALTHAM, Mass., April 10, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company developing novel precision antibacterials to treat...
Entasis Therapeutics Initiates Global Phase 3 Pivotal Trial of ETX2514SUL for Patients with Carbapenem-Resistant Acinetobacter Infections
April 04, 2019 08:00 ET
|
Entasis Therapeutics Holdings Inc.
WALTHAM, Mass., April 04, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company developing novel antibacterials to treat serious...
Entasis Therapeutics to Present at H.C. Wainwright & Co. Global Life Sciences Conference in London
April 02, 2019 08:00 ET
|
Entasis Therapeutics Holdings Inc.
WALTHAM, Mass., April 02, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel...
Entasis Therapeutics Reports Full Year 2018 Financial Results and Provides Business Update
March 29, 2019 07:30 ET
|
Entasis Therapeutics Holdings Inc.
WALTHAM, Mass., March 29, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel...
Entasis Therapeutics to Present at the 39th Annual Cowen Healthcare Conference
March 06, 2019 16:01 ET
|
Entasis Therapeutics Holdings Inc.
WALTHAM, Mass., March 06, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel...
Entasis Therapeutics Receives Positive Feedback from FDA End-of-Phase 2 Meeting for ETX2514SUL; Signs Rapid Diagnostic Agreement with bioMérieux
February 05, 2019 08:00 ET
|
Entasis Therapeutics Holdings Inc.
WALTHAM, Mass., Feb. 05, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel...
Entasis Therapeutics to Present at the BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference
December 05, 2018 08:00 ET
|
Entasis Therapeutics Holdings Inc.
WALTHAM, Mass., Dec. 05, 2018 (GLOBE NEWSWIRE) -- Entasis Therapeutics (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial...
Entasis Therapeutics Reports Third Quarter 2018 Financial Results and Provides Business Update
November 14, 2018 08:00 ET
|
Entasis Therapeutics Holdings Inc.
Completed $75.0 million initial public offering in September Reported positive Phase 2 topline results of lead program ETX2514SUL On-track to initiate two Phase 3 clinical trials in 2019 WALTHAM,...
Entasis Therapeutics Announces Zoliflodacin Phase 2 Results Published in The New England Journal of Medicine
November 07, 2018 17:00 ET
|
Entasis Therapeutics Holdings Inc.
Zoliflodacin Was Well-Tolerated and Successfully Treated Substantially All Uncomplicated Gonorrhea Cases Phase 3 clinical trial, in partnership with GARDP, to begin in 2019 WALTHAM, Mass., Nov. 07,...